NL-OMON39315已完成2 期
ME-Lung 3. A Phase I/II study of continuous oral treatment with BIBF 1120 added to standard gemcitabine/cisplatin therapy in first line NSCLC patients with squamous cell histology. - LUME-Lung 3
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •- Diagnosis of stage IIIB/IV or recurrent NSCLC with squamous histology
- •- Measurable disease according to RECIST 1.1
- •- ECOG score 0-1
- •- For phase 2: radiologically confirmed at least stable disease after 2 prior cycles of cisplatin/gemcitabine chemotherapy
排除标准
- •- Prior therapy for advanced, metastatic, or recurrent NSCLC. Prior neoadjuvant and/or adjuvant therapy is allowed if at least 12 months have elapsed between the end of the treatment and randomization
- •- Prior treatment with other VEGFR inhibitors (other than bevacizumab)
- •- Known pre-existent interstitial lung disease
- •- Active brain metastases
- •- Recent radiotherapy
研究者
相似试验
进行中（未招募）
1 期
A Phase I/II study of continuous oral treatment with BIBF 1120 added to standard gemcitabine/cisplatin therapy in first line NSCLC patients with squamous cell histology.EUCTR2010-019707-32-GBBoehringer Ingelheim21
进行中（未招募）
不适用
A study of BIBF 1120 added to standard chemotherapy in patients with a specific type of lung cancerAdvanced Non Small Cell Lung Cancer (recurrent or stage IIIB/IV) with squamous cell histology.MedDRA version: 14.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: LLTClassification code 10001184Term: Adenocarcinoma of lung stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: LLTClassification code 10001183Term: Adenocarcinoma of lung stage IIIBSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: LLTClassification code 10001177Term: Adenocarcinoma of lung recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-019707-32-NLBoehringer Ingelheim bv150
进行中（未招募）
不适用
ME-Lung 3. A Phase I/II study of continuous oral treatment with BIBF 1120 added to standard gemcitabine/cisplatin therapy in first line NSCLC patients with squamous cell histology. - LUME-Lung 3Advanced Non Small Cell Lung Cancer (recurrent or stage IIIB/IV) with squamous cell histology.MedDRA version: 12.1Level: LLTClassification code 10001183Term: Adenocarcinoma of lung stage IIIBMedDRA version: 12.1Level: LLTClassification code 10001184Term: Adenocarcinoma of lung stage IVMedDRA version: 12.1Level: LLTClassification code 10001177Term: Adenocarcinoma of lung recurrentMedDRA version: 12.1Level: LLTClassification code 10061873Term: Non-small cell lung cancerEUCTR2010-019707-32-PTBoehringer Ingelheim150
进行中（未招募）
不适用
A Phase I/II study of continuous oral treatment with BIBF 1120 added to standard gemcitabine/cisplatin therapy in first line NSCLC patients with squamous cell histology.Advanced Non Small Cell Lung Cancer (recurrent or stage IIIB/IV) with squamous cell histology.MedDRA version: 14.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: LLTClassification code 10001184Term: Adenocarcinoma of lung stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: LLTClassification code 10001183Term: Adenocarcinoma of lung stage IIIBSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: LLTClassification code 10001177Term: Adenocarcinoma of lung recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-019707-32-DEBoehringer Ingelheim Pharma GmbH & Co. KG150
已完成
不适用
Safety evaluation of long-term NMN in healthy peopleJPRN-jRCTs031180242Itoh Hiroshi30